A prospective, observational study of cetuximab relative dose intensity in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
Latest Information Update: 18 Oct 2017
Price :
$35 *
At a glance
- Drugs Cetuximab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms DIRECT
- 12 Oct 2017 Results presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 05 Dec 2016 New trial record
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress